l General Information |
Product Name | BAW2881 |
General description | BAW2881 is a novel vascular endothelial growth factor (VEGF) receptor tyrosine-kinase inhibitor that potently inhibits VEGFR1-3 at 1.0-4.3 nanomolar (nM) concentrations and inhibits PDGFRβ, c-Kit, and RET at 45-72 nM concentrations. |
Synonym | NVP-BAW2881 |
Purity | ≥97.0%(HPLC) | CAS Number | 861875-60-7 |
Formula | C22H15F3N4O2 | Molecular Weight | 424.38 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Solid |
Solubility(25°C) | DMSO | ≥50mg/mL |
Ethanol | ≥15mg/mL |
Water | Very slightly soluble |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
